On July 2, MicroPort MedBot-B rose 5.32% in regular trading, trading at 23.54 HKD/share, with turnover of approximately 26.04 million HKD.

The rally was driven by continued market reaction to the company's announcement that its core product, the Toumai laparoscopic surgical robot, surpassed 200 commercial installations globally. The 200th unit was deployed at Spain's top medical institution HM Hospitales, with all installations having received end-customer acceptance reports. Furthermore, Toumai's global commercial orders have exceeded 300 units, with total orders approaching 400. New orders secured in the first half already surpass the full-year total of last year.

Adding to the positive momentum, Toumai's remote surgery full-department application received EU CE certification in June, making it the world's first remote surgical robot to obtain this approval. Multiple institutions including UBS, JP Morgan, and CITIC Construction Investment have issued positive ratings, citing strong overseas sales potential and expectations that the company could achieve breakeven in the first half of the year, with overseas revenue projected to exceed 80% of total revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)